Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia.
Roth
Bryan L
BL
Department of Biochemistry, National Institute of Mental Health Psychoactive Drug Screening Program, Case Western Reserve University Medical School, Cleveland, Ohio, USA. bryan_roth@med.unc.edu
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D008967:Molecular Biology; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics; D049490:Systems Biology
D014150:Antipsychotic Agents